Pivotal Life Sciences — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)Genesys CapitalHealthCapLumira VenturesSeroba Life SciencesVenture Ontario+6 more
This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.
Biotech
Co-investorsCDP Venture CapitalIreland Strategic Investment FundAdams Street PartnersGenesys CapitalHealthCapOrbiMed+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Inozyme
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.













